TY - JOUR
T1 - ChAdOx1 vaccination, blood coagulation, and inflammation
T2 - No effect on coagulation but increased interleukin-6
AU - Willems, Loes H.
AU - Nagy, Magdolna
AU - ten Cate, Hugo
AU - Spronk, Henri M. H.
AU - Jacobs, Lotte M. C.
AU - Kranendonk, Josephine
AU - van Leeuwen, Maaike
AU - Meijer, Danielle
AU - Middeldorp, Saskia
AU - Groh, Laszlo A.
AU - Warlé, Michiel C.
N1 - Funding Information: The authors thank Tjarda Tromp who provided assistance and support for the practical execution of this study, and Trix the Boer for assistance and coordination of the laboratory processes. Publisher Copyright: © 2021 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Background: Vaccination is the leading approach in combatting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. ChAdOx1 nCoV-19 vaccination (ChAdOx1) has been linked to a higher frequency of rare thrombosis and thromboembolism. This study aimed to explore markers related to the blood coagulation system activation and inflammation, before and after ChAdOx1 vaccination. Patients and Methods: An observational cohort study including 40 health care workers. Whole blood samples were collected before, and either 1 or 2 days after vaccination. Activated coagulation factors in complex with their natural inhibitors were determined by custom ELISAs, including thrombin:antithrombin (T:AT), kallikrein:C1-esterase-inhibitor (PKa:C1Inh), factor(F)IXa:AT, FXa:AT, FXIaAT, FXIa:alpha-1-antitrypsin (α1AT), FXIa:C1inh, and FVIIa:AT. Plasma concentrations of interleukin (IL)-6 and IL-18 were quantified via ELISA. Analyses were performed using Wilcoxon signed-rank test. Results: Levels of FVIIa:AT decreased with a median (IQR) of 707 (549–1028) pg/ml versus 598 (471–996) pg/ml, p = 0.01; and levels of IL-6 increased, 4.0 (1.9–6.8) pg/ml versus 6.9 (3.6–12.2) pg/ml, p = 0.02, after vaccination. No changes were observed in T:AT, PKa:C1Inh, FIXa:AT, FXa:AT, FXIaAT, FXIa:α1AT, FXIa:C1inh, and IL-18. Conclusion: ChAdOx1 leads to an inflammatory response with increased levels of IL-6. We did not observe activation of the blood coagulation system 1–2 days following vaccination.
AB - Background: Vaccination is the leading approach in combatting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. ChAdOx1 nCoV-19 vaccination (ChAdOx1) has been linked to a higher frequency of rare thrombosis and thromboembolism. This study aimed to explore markers related to the blood coagulation system activation and inflammation, before and after ChAdOx1 vaccination. Patients and Methods: An observational cohort study including 40 health care workers. Whole blood samples were collected before, and either 1 or 2 days after vaccination. Activated coagulation factors in complex with their natural inhibitors were determined by custom ELISAs, including thrombin:antithrombin (T:AT), kallikrein:C1-esterase-inhibitor (PKa:C1Inh), factor(F)IXa:AT, FXa:AT, FXIaAT, FXIa:alpha-1-antitrypsin (α1AT), FXIa:C1inh, and FVIIa:AT. Plasma concentrations of interleukin (IL)-6 and IL-18 were quantified via ELISA. Analyses were performed using Wilcoxon signed-rank test. Results: Levels of FVIIa:AT decreased with a median (IQR) of 707 (549–1028) pg/ml versus 598 (471–996) pg/ml, p = 0.01; and levels of IL-6 increased, 4.0 (1.9–6.8) pg/ml versus 6.9 (3.6–12.2) pg/ml, p = 0.02, after vaccination. No changes were observed in T:AT, PKa:C1Inh, FIXa:AT, FXa:AT, FXIaAT, FXIa:α1AT, FXIa:C1inh, and IL-18. Conclusion: ChAdOx1 leads to an inflammatory response with increased levels of IL-6. We did not observe activation of the blood coagulation system 1–2 days following vaccination.
UR - http://www.scopus.com/inward/record.url?scp=85121770601&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/rth2.12630
DO - https://doi.org/10.1002/rth2.12630
M3 - Article
C2 - 34934894
SN - 2475-0379
VL - 5
JO - Research and practice in thrombosis and haemostasis
JF - Research and practice in thrombosis and haemostasis
IS - 8
M1 - e12630
ER -